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Purpose: This study aimed to delineate the genetic basis of
congenital ocular motor apraxia (COMA) in patients not otherwise
classifiable.
Methods: We compiled clinical and neuroimaging data of
individuals from six unrelated families with distinct clinical features
of COMA who do not share common diagnostic characteristics of
Joubert syndrome or other known genetic conditions associated
with COMA. We used exome sequencing to identify pathogenic
variants and functional studies in patient-derived fibroblasts.
Results: In 15 individuals, we detected familial as well as de novo
heterozygous truncating causative variants in the Suppressor of
Fused (SUFU) gene, a negative regulator of the Hedgehog (HH)
signaling pathway. Functional studies showed no differences in cilia
occurrence, morphology, or localization of ciliary proteins, such as
smoothened. However, analysis of expression of HH signaling
target genes detected a significant increase in the general signaling
activity in COMA patient–derived fibroblasts compared with
control cells. We observed higher basal HH signaling activity
resulting in increased basal expression levels of GLI1, GLI2, GLI3,
and Patched1. Neuroimaging revealed subtle cerebellar changes, but
no full-blown molar tooth sign.
Conclusion: Taken together, our data imply that the clinical
phenotype associated with heterozygous truncating germline
variants in SUFU is a forme fruste of Joubert syndrome.
Genetics in Medicine (2021) 23:341–351; https://doi.org/10.1038/s41436-
020-00979-w
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INTRODUCTION
The term congenital ocular motor apraxia (COMA), intro-
duced by Cogan in 1952, designates the inability to initiate
saccades, i.e., the eye movements performing rapid gaze shift.
In his original report, Cogan described four children with a
distinct disturbance of voluntary horizontal gaze character-
ized by the “inability to turn the eyes voluntarily in a direction
for which there is full involuntary…control” accompanied by
compensatory, jerky head movements.1 COMA usually affects
horizontal, but rarely also vertical saccades.
Ocular motor apraxia (OMA) is observed in a wide range of
conditions.2 A frequent and consistent co-occurrence of early-
onset (congenital) OMA, also designated infantile-onset
saccade initiation delay, with early-onset cerebellar ataxia
and global developmental delay was emphasized.3–9 Most of
the patients described experienced gradual resolution of OMA
and ataxia over their first decade of life, whereas cognitive
impairment persisted to a variable extent.4,7–9 These reports
shaped a concept of COMA as a clinical entity and likely
inherited as an autosomal recessive disorder, although Cogan,
in his original report, described COMA as a symptom, not a
diagnosis. However, no gene associated with isolated COMA
(OMIM 257550) has been identified yet.
Of note, this condition is sometimes also called Cogan
syndrome type 2, thus distinguishing it from Cogan syndrome
type 1, a rare inflammatory disorder characterized by
interstitial keratitis and sensorineural hearing loss, occasion-
ally accompanied by systemic vasculitis.
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More recently, doubts have arisen “whether Cogan-type
oculomotor apraxia can exist as an isolated entity.”10 Liu and
coworkers11 assigned COMA to three major clinical condi-
tions: (1) benign or idiopathic variant with normal neuroima-
ging and only occasionally occurring neurologic symptoms;
(2) nonprogressive, noninherited variant with structural brain
anomaly caused, e.g., by dysgenesis of the cerebellar vermis or
corpus callosum, inferior vermian hypoplasia, Dandy–Walker
malformation, gray matter heterotopias, and perinatal ische-
mia; and (3) “part of a genetic syndrome” variant, which
includes, e.g., Joubert syndrome, Jeune syndrome, and a
subset of patients with Leber congenital amaurosis.
In a previous study aimed at a nosological delineation of
COMA, we investigated a cohort of 21 patients diagnosed as
having COMA.12 In that study, a reappraisal of neuroimaging
revealed a molar tooth sign (MTS) indicative of Joubert
syndrome in 11 and specific neuroimaging features pointing
to other diagnoses in 2 patients. The remaining eight subjects
had normal magnetic resonance image (MRI) or nonconclu-
sive neuroimaging features, which led to a descriptive
diagnostic classification of COMA.12
Pursued investigation of these eight patients and recruit-
ment of further subjects with COMA framed the study
presented here. We report six unrelated families comprising
15 affected individuals with distinct clinical features of
COMA who do not share common diagnostic characteristics
of Joubert syndrome or other known genetic conditions. We
identified heterozygous truncating germline variants in the
Suppressor of Fused (SUFU) gene and were able to show de
novo occurrence of these SUFU variants in two families and
inheritance from a mildly affected parent in the remaining
four families. On a cellular level, COMA patient–derived
fibroblasts show a generally high basal Hedgehog (HH)
signaling activity, which, however, can be regulated by
exogenous HH signaling activator or inhibitor treatment.
MATERIALS AND METHODS
Subjects
We compiled clinical data of 15 subjects from six unrelated
families. Clinical phenotypes and MRI data of three subjects
were included in our previous report.12 An additional six
subjects with heterozygous SUFU variants and, in most cases,
early-onset ocular apraxia were recruited from the families of
these three index patients. Six further subjects, five of them
with COMA, from three families were recruited through
national and international collaborations with the attending
neurologists.
Ethics statement
All studies were performed in accordance with the Declara-
tion of Helsinki protocols. The studies were reviewed and
approved by the local institutional ethics board (University
Medical Center Göttingen, Göttingen, Germany; file numbers
19/5/14 and 3/9/14). Written informed consent was obtained
from all affected subjects, parents, or legal representatives
participating in this study.
Clinical and qualitative neuroimaging analysis
Data on developmental course and neurological features were
collected by review of the clinical histories and by
clinical–neurological follow-up investigations. Information
about ophthalmological features was compiled from neuro-
ophthalmological or pediatric neurological reports. Cognitive
function was assessed using standardized neuropsychological
tests whenever possible, or it was appraised from the patient’s
history, clinical examination, and school reports. Additional
information was gathered in telephone interviews with the
patients or their parents using a standardized questionnaire.
Neuroimaging data were available for ten subjects. Two
subjects received a new MRI in line with this study for
technically optimized assessment of the hindbrain. All
available MRI data sets were qualitatively analyzed by two
pediatric neurologists with experience in neuroimaging of the
brainstem and cerebellum. All imaging sequences in axial,
coronal, and sagittal orientation were scrutinized with a focus
on size and position of the superior cerebellar peduncles,
hypo-/dysplasia of the cerebellar vermis, cerebellar cysts,
brainstem morphology including shape of the interpeduncu-
lar fossa at the section of the brainstem isthmus and upper
pons, size and shape of the 4th ventricle, and any other
cerebellar or cerebral malformations, as described
previously.12
Exome sequencing and variant screening
In families 1, 2, 3, and 6,13 trio-based exome sequencing (ES)
was performed. In family 4, a next-generation sequencing
(NGS) panel of 13 genes associated with ciliopathies was
applied. All detected SUFU variants were confirmed by
polymerase chain reaction (PCR) amplification and subse-
quent Sanger sequencing on an independent DNA sample
and tested for cosegregation within the respective families. In
the affected subject II.1 of family 5, all exons and adjacent
exon–intron boundaries of SUFU were analyzed by PCR and
subsequent, bidirectional Sanger sequencing in a candidate
gene approach.
Details of ES and variant screening as well as methods of
cell culture and treatments, analysis of cilia formation,
immunofluorescence staining, real-time quantitative PCR,
and statistical analysis are provided as Supplementary
Information.
RESULTS
Clinical and neuroimaging phenotypes of individuals with
COMA
Through national and international collaborations, we
recruited 15 individuals from six families with a clinical
diagnosis of COMA and without conclusive neuroimaging
features, notably without definite molar tooth sign. Three of
these patients, III.6 (family 1), II.1 (family 2), and II.1 (family
3), were presented in a previous clinical study without any
genetic findings.12 Detailed clinical information of affected
individuals is summarized in Table 1. Brain MRI was available
from ten subjects including four from a parent, and was
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deemed conspicuous in families 3 through 6 already at first
evaluation. Standardized qualitative reanalysis of all MRI data
sets revealed strikingly similar neuroimaging features in all
subjects. Figure 1 illustrates the relevant findings from three
individuals in comparison with a healthy control. We did not
observe any signs of a classical, full-blown molar tooth sign.
However, the superior cerebellar peduncles were abnormally
prominent in all cases, thickened, elongated, and had a more
horizontal course, best seen in parasagittal sections. On axial
sections through the upper vermis, a cerebellar folia dysplasia
a b c d
e f g h
i j k l
m n o p
Fig. 1 Characteristic magnetic resonance image (MRI) features in three subjects with heterozygous SUFU variants. Four representative T1-
weighted MRIs (arranged in horizontal rows) are shown from three individuals with SUFU variants and one adult healthy control (m–p). Panels (a–d) are from
subject I.1, family 3, at age 1.5 years; (e–h) from subject II.1, family 2, at age 7.5 years; and (i–l) from subject II.1, family 5, at age 40 years. The first vertical
row (a,e,i,m) shows axial views at the level of the upper vermis, indicating folial dysplasia (arrow). The second vertical row (b,f,j,n) illustrates axial views at
the level of the superior cerebellar peduncles (arrows), these are more prominent (longer, thicker) compared with normal. The third vertical row (c,g,k,o)
shows parasagittal sections demonstrating that the superior cerebellar peduncles (arrows) are thicker and have a more horizontal course compared with
normal (o). The fourth vertical row (d,h,l,p) illustrates coronal images revealing irregular folia and vermis splitting (arrows) in the individuals with SUFU
variants.
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was obvious in eight cases and present in a milder form in two
individuals. Coronal views were available in seven subjects
and revealed an upper vermis split in all seven cases. The
interpeduncular fossa had a normal appearance. The fourth
ventricle had a normal shape and, on midsagittal view, the
fastigium was not cranially displaced. Supratentorial anoma-
lies were not discernible (Fig. 1). Of note, vermis folia
dysplasia and upper vermis split are typical findings in
Joubert syndrome.14
Family 1
Family 1 is a multigenerational family with several individuals
showing clinical features of OMA. Individual II.8 was
diagnosed with early-onset OMA at the age of five months.
During childhood, ataxia, global developmental delay, and
learning disability became apparent. His maternal half-sister,
individual II.3, had delayed motor and speech development.
She attended a special school due to learning disability. She
reports no head jerks or problems with horizontal pursuit,
and her relative recalled no signs of OMA during her
childhood. Her son (III.3) was diagnosed with OMA at the
age of five months. He presented with ataxia, delay in motor
and speech development as well as cognitive impairment.
Individual II.5, the sister of II.3, had normal motor, speech,
and cognitive development. Early OMA is not recalled by
other, older family members. She attended regular school, is
now a housewife and mother, and has no vocational training.
Her son, individual III.6, presented with early-onset OMA,
ataxia, motor and speech developmental delay as well as
cognitive impairment. Clinical data for individual I.2, the
mother of II.3, II.5, and II.8, was limited, but delay in speech
development was reported during early childhood.
Family 2
Individual II.1 was diagnosed with early-onset OMA, ataxia,
and delay in motor and speech development (Fig. 1e–h). His
cognitive performance is normal. His father, individual I.1,
was allegedly healthy. However, clinical re-evaluation and
consultation of the paternal grandmother revealed motor
developmental delay with impaired balance in his first years
of life. He walked without support at two years three months
and had poor motor coordination throughout kindergarten
age. Abnormal eye movements or head jerks were not noted.
He learned “very late” to ride a bicycle and tie his shoes. At
school, he easily learned reading, but was not able to write
properly. Over the years, these symptoms ameliorated and he
was unimpaired as an adult.
Family 3
Individual II.1 had early-onset OMA, but normal motor,
speech, and cognitive development. Mild balance problems
were observed in her first years of life, but overt ataxia was not
reported in repeated neurological examinations over the years
(Fig. 1a–d). She presented with secondary macrocephaly with
a head circumference of +2.6 SD at last follow-up at age nine
years, while the head circumferences of both parents are
normal. She had surgical excision of a digital tumor at age six
years. Histopathological investigation of the excised tissue
revealed a single fibroma without evidence of malignancy.
There are no additional clinical signs pointing toward
Gorlin–Goltz syndrome (OMIM 109400) in this patient.
Family 4
Individual II.1 presented with early-onset COMA. The boy
showed mild motor developmental delay, muscular hypoto-
nia, and early-onset ataxia. His speech development is
currently normal and his cognitive development seems to be
normal, but assessment is unsecure at age of only 2 years.
Clinical evaluation of his parents did not reveal any sign
of OMA.
Family 5
Individual II.1 presented with early-onset OMA, ataxia, and
motor as well as speech development delay. As his
neuroimaging features showed overlap with patterns observed
in other patients of this study, direct testing of SUFU was
initiated (Fig. 1i–l). His father, individual I.1, had a
longstanding history of ophthalmological treatment including
several surgical interventions for strabismus. His mother used
to urge him to practice horizontal gaze pursuit, and he is
accustomed to his jerky head movements. Currently, he shows
mild impairment of horizontal saccades and occasional head
jerks. A diagnosis of OMA was not established previously,
however, and onset of OMA cannot be determined. His
cognitive development was normal and he accomplished an
academic career.
Family 6
Individual II.1 and his younger brother II.2 were both
diagnosed with early-onset OMA at the age of 6 and
10 months, respectively. Both had early-onset ataxia,
muscular hypotonia, and mild motor as well as speech
developmental delay. Neuroimaging features of individual II.1
resembled the pattern observed in other patients in this study.
A heterozygous SUFU variant was identified using ES. Clinical
history of their mother, individual I.2, revealed unaided
walking at two years of age, mainly due to sickle feet. Besides
this, her motor and cognitive development was normal and
OMA was not reported in childhood nor present in
adulthood.
Identification of heterozygous truncating SUFU variants
To identify the underlying genetic cause of COMA, we
performed ES of affected individuals from families 1, 2, 3, 4,
and 6 and their parents. ES data were filtered for de novo,
homozygous, or compound heterozygous variants with a
coverage of more than six reads, a minimum quality score of
10, an allele frequency ≥25%, and an minor allele frequency
(MAF) <0.5% in the gnomAD database.15 Based on the
similar clinical presentation, we filtered for variants in
overlapping genes in all affected individuals in these families,
and we were able to identify variants in only a single
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overlapping gene in all five families. All affected individuals
carried heterozygous truncating variants in the SUFU gene
(Fig. 2).
In individuals II.1 (family 3) and II.1 (family 4) we
identified the heterozygous truncating variants c.479delA (p.
His160Leufs*20) and c.1220_1221insT (p.Phe408Valfs*13) in
SUFU, respectively, and we confirmed the de novo status of
these variants in the affected individuals. Individuals III.3
(family 1), II.1 (family 2), and II.1 and II.2 (family 6) inherited
SUFU variants from one of their parents, and clinical re-
evaluation revealed mild to moderate clinical symptoms in
individual II.3 (family 1), I.1 (family 2), as well as I.2 (family
6). In individual II.1 (family 5), we analyzed all exons and
exon–intron boundaries in SUFU by Sanger sequencing in a
candidate gene approach based on the characteristic MRI
features. We identified a heterozygous frameshift variant,
c.309_310delAG (p.Arg103Serfs*3), in SUFU that was
inherited by the affected father.
All six variants were not observed in any current database of
human genetic variations including gnomAD (access date 26
April 2020), and they are predicted to lead to SUFU protein
truncation (Fig. 3). SUFU is a highly conserved protein that is
under strict mutational constraint. In gnomAD, which
contains the genetic data of more than 250,000 alleles, only
194 missense variants were observed while 286 were expected
for SUFU, resulting in a z-score of 1.93. Moreover, no
homozygous truncating variants were observed in SUFU and
only three heterozygous truncating variants were detected in
gnomAD (probability of loss of function intolerance [pLI]
score of 1), indicating that SUFU is extremely intolerant to
loss-of-function variants.
SUFU variants lead to impaired repression of HH signaling
signature genes
SUFU is a negative regulator of the HH signaling pathway. In
the absence of active HH signaling, SUFU binds to cytosolic
GLI proteins, thereby restricting their activity and inducing
their truncation, which in turn promotes GLI repressor
formation and induces repression of their target gene
expression. Since the existence of intact primary cilia is
required for HH signaling in vertebrates, we first analyzed
whether patient-derived fibroblasts form acetylated tubulin
positive cilia. However, we did not observe any differences in
cilia occurrence, morphology, or ciliary localization of SMO in
patient-derived fibroblasts compared with wild-type cells,
indicating that the identified truncating variants in SUFU
have no impact on this organelle essential for HH signaling
(Fig. 4a). To assess whether the SUFU variants have an effect
on the repressor function of SUFU, we analyzed the expression
of HH signaling target genes in wild-type and COMA
patient–derived dermal fibroblasts by quantitative real-time
PCR (Fig. 4b and S1). Interestingly, we observed a significant
increase in the general activity in COMA patient–derived
fibroblasts compared with control cells resulting in higher
basal expression levels of GLI1, GLI2, GLI3, and PTCH1
(Fig. 4b). Treatment of cells with the HH signaling agonist
SAG led to a further increase in target gene expression in both
wild-type and patient-derived fibroblasts, with higher expres-
sion levels in patient-derived cells (Fig. S1). Similarly,
inhibition of HH signaling using the Smoothened inhibitor
vismodegib downregulates HH signaling and target gene
expression to respective basal levels, still resulting in higher
activity in vismodegib-treated patient fibroblasts compared
with wild-type fibroblasts (Fig. S1). Nevertheless, the extent of
HH signaling regulation upon SAG and/or vismodegib
treatment did not differ between COMA patient–derived
and control fibroblasts (Fig. S1). Overall, these results suggest
that the identified truncation variants in SUFU lead to higher
basal HH signaling activity, which, however, can be regulated
by exogenous activator or inhibitor treatment, indicating an
impaired endogenous repression of HH signaling and thus a
compromised inhibition of HH target gene expression.
DISCUSSION
In this study aimed at identification of the gene associated
with COMA in patients who show no conclusive neuroima-
ging features at initial evaluation and, in particular, do not
fulfill diagnostic criteria of Joubert syndrome (definite molar
tooth sign), we detected heterozygous variants of SUFU in
15 subjects from six unrelated families of various ethnic
backgrounds. Early-onset (congenital) ocular apraxia was well
documented in ten patients. Eight of them showed additional
neurological features including early-onset ataxia and devel-
opmental delay, with some phenotypic variability. Among the
parents carrying familial SUFU variants, two had no history of
OMA or other neurological features (II.5 family 1, I.2 family
6), one had motor and speech developmental delay as well as
motor incoordination in his first years of life that regressed
completely until adult age (I.1 family 2), one showed speech
developmental delay during early childhood (I.2, family 1),
and one shows mild OMA at adult age with unknown onset
(I.1, family 5).
Of note, the neuroimaging features consistently comprise
abnormalities of the superior cerebellar peduncles and the
upper cerebellar vermis, but no full-blown molar tooth sign as
seen in typical Joubert syndrome. The molar tooth, now
considered pathognomonic for Joubert syndrome, arises from
the combination of elongated, thickened, and horizontally
oriented superior cerebellar peduncles, hypo-/dysplasia of the
cerebellar vermis with rostral shifting of the fastigium, and an
abnormally deep interpeduncular fossa at the section of the
brainstem isthmus and upper pons.16 However, it is worth
mentioning that a milder variant of the molar tooth sign was
occasionally observed in patients carrying variants in certain
Joubert genes including NPHP1, C5orf42, SUFU, and
FAM149B1.17–20 These observations may suggest that the
neuroimaging features in certain forms of COMA and in
Joubert syndrome constitute a continuous spectrum. From
our experience, a clear distinction between a definite molar
tooth sign and a milder hindbrain malformation as described
here is occasionally challenging, even with a technically
optimal MRI investigation.
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Fig. 2 Pedigrees and genetic characterization of six families with congenital ocular motor apraxia carrying heterozygous loss-of-function
variants in SUFU. (a) Pedigrees of families 1–6 showing segregation of rare deleterious SUFU variants. Unfilled shapes denote healthy, filled shapes
affected individuals. (b) Chromatograms of the identified SUFU variants in family 1 (F1: c.83C>A; p.Ser28*), family 2 (F2: c.1099G>T; p.Glu367*), family 3
(F3: c.479delA; p.His160Leufs*20), family 4 (F4: c.1220_1221insT; p.Phe408Valfs*13), family 5 (F5: c.309_310delAG; p.Arg103Serfs*3), and family 6 (F6:
c.1333dupG; p.Glu445Glyfs*22) compared with wild-type (WT) sequences of the respective positions. Localization of frameshift or nonsense variants is
indicated in red.
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Fig. 4 Cilia formation and expression of Hedgehog signaling signature genes in congenital ocular motor apraxia (COMA) patient–derived
dermal fibroblasts. (a) Representative pictures of double immunofluorescent staining for visualization of SMO (upper row in monochrome, third and
lower row in red) and acetylated tubulin (acetyl.tubulin) (second row in monochrome, third and lower row in green) in control fibroblasts and fibroblasts
derived from affected individual II.2 (family 3, first column), individual II.1 (family 2, middle column), and individual II.1 (family 4, right column). Nuclei were
visualized by DAPI staining (lower row in blue). Scale bars: 1 µm. (b) Quantitative real-time polymerase chain reaction (PCR)–based expression analyses of the
Hedgehog signaling signature genes GLI1, GLI2, GLI3, and PTCH1 normalized to 18S ribosomal RNA (rRNA) (left column) or HPRT (right column) expression
levels, respectively, of controls (N= 5) and COMA patient–derived fibroblasts (COMA) (N= 4). Shown results represent data of two different cellular
passages per fibroblast culture each analyzed in biological triplicates (gray circles) that were measured in technical triplicates. Total mean values +/- SEM of
all analyzed samples are indicated in black. Significant differences were tested by nonparametric Mann–Whitney tests. *p < 0.05; **p < 0.01; ***p < 0.001.
No significantly different expression levels were observed in the five independent control fibroblast cultures, different cellular passages, or biological
triplicates. For comparison of individual gene expression levels of the four independent COMA patient–derived fibroblast cultures as well as HIP expression
levels see Supplemental Data (Fig. S1).
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A separation of SUFU-associated COMA as reported here
and Joubert syndrome based solely on clinical criteria is even
more difficult and will not be possible in many cases. The
clinical spectrum of Joubert syndrome encompasses a wide
range of phenotypes spanning from mild variants with
muscular hypotonia, ataxia, OMA, and benign developmental
delay to severe forms with pronounced, sometimes progres-
sive, multisystem disorder.14,16 Thus, there is considerable
phenotypic overlap between these conditions.
The SUFU variants that we detected in the subjects
described here were exclusively truncating variants. These
variants are distributed over the entire protein (Fig. 3), thus
making haploinsufficiency the most likely underlying patho-
physiological mechanism. On a cellular level, these variants
seem not to impair the occurrence, morphology or SMO
localization of the primary cilium. SUFU is a major inhibitor
of HH signaling, which is an evolutionary highly conserved
pathway that plays an important role in embryonic develop-
ment, stem cell maintenance, and tissue homeostasis.
In knockout mice with SuFu deficiency targeted to the
cerebellum and some parts of the midbrain, it was demon-
strated that SuFu is required for proper midhindbrain
patterning, controls cerebellar patterning by regulating cell
differentiation and migration, and regulates the localization
and level of SHH signaling and the levels of GLIs, GLI3R in
particular, and that GLI3R partially mediates SuFu functions
during cerebellar morphogenesis.21 This prompted us to
analyze the mutational impact on this pathway. Interestingly,
we observed a higher basal activity of HH signaling in COMA
patient–derived fibroblasts compared with control cells,
supporting the hypothesis that the inhibitory function of
SUFU is impaired by the identified SUFU variants. SAG-
induced stimulation of HH signaling led to a further increase
in target gene expression levels in both wild-type and patient-
derived fibroblasts, whereas inhibition of HH signaling by the
Smoothened inhibitor vismodegib reduced HH signaling and
target gene expression to the respective basal levels. This
shows that although basal activity of the HH signaling
pathway is higher in COMA patient cells, pathway regulation
is not impaired. Remarkably, COMA patient–derived fibro-
blasts show a similar fold change of HH pathway activation
and repression as wild-type cells, if values were normalized to
the respective basal levels.
Interestingly, germline heterozygous truncating and loss-of-
function variants in SUFU (OMIM *607035) were observed in
the basal cell nevus syndrome (BCNS, Gorlin–Goltz syn-
drome, OMIM 109400), a cancer-predisposing condition with
variable developmental and skeletal anomalies.22,23 BCNS
may also be associated with a heterozygous germline
pathogenic variant in PTCH1. BCNS is mainly characterized
by lamellar calcification of the falx, jaw keratocysts, palmar/
plantar pits, and multiple basal cell carcinomas as major
diagnostic criteria. Additionally, childhood medulloblastoma,
lymphomesenteric or pleural cysts, macrocephaly, cleft lip/
palate, vertebral/rib anomalies (bifid/splayed/extra ribs; bifid
vertebrae), preaxial or postaxial polydactyly, ovarian/cardiac
fibromas, and ocular anomalies can be observed in patients
with BCNS.24 Among the 11 subjects with heterozygous
SUFU variants reported here, two showed macrocephaly and
one had borderline head circumference (+2.0 SD; I.1 family
2). Subject II.1 from family 3 carrying the de novo
heterozygous SUFU variant c.479delA shows secondary,
nonfamilial macrocephaly as a feature consistent with BCNS.
At age six years a single digital fibroma was excised. In BCNS,
ovarian and cardiac fibromas are minor diagnostic criteria,
but digital fibromas were not reported, to our knowledge.
Subject I.1 from family 5 shows macrocephaly (+3.0 SD) and
tall stature (body height 195 cm, +2.1 SD). Parental head
circumferences were not available.
Besides this, we found no other features consistent with
BCNS based on physical examination and ultrasound. Thus,
the condition reported here and SUFU-associated BCNS are
likely allelic disorders, as there is currently no convincing
evidence for a clinical overlap. Both, somatic and germline
(heterozygous and biallelic) variants in SUFU were found to
be associated with cerebellar medulloblastoma.25 A hetero-
zygous truncating germline variant in SUFU was observed in
familial meningioma.26 Given the fact that haploinsuffi-
ciency caused by truncating loss-of-function variants
throughout SUFU is the underlying molecular mechanism
in both COMA and BCNS, additional genetic and/or
nongenetic modifiers must exist that drive the phenotypic
expression toward a specific clinical entity. We did not
observe any clusters of variants in SUFU or other pathway
genes in our exome data, which might point toward a
genetic modifier. However, the number of patients available
for this analysis was limited. Consequently, larger cohorts of
patients with COMA and BCNS are needed in future studies
to identify these modifying factors that are determining the
phenotypic outcome of heterozygous loss-of-function var-
iants in SUFU.
More recently, germline biallelic pathogenic variants of
SUFU were shown to impair SHH signaling and to be
associated with Joubert syndrome type 32 (OMIM 617757).19
Homozygous missense variants in SUFU were detected in four
children from two unrelated families. All subjects showed
facial dysmorphism including hypertelorism; broad,
depressed nasal bridge; and frontal bossing, as well as
developmental delay with mild intellectual impairment, gait
ataxia, and dysarthria. Three of them had postaxial poly-
dactyly and two had global macrosomia with macrocephaly.
Neuroimaging revealed cerebellar vermis hypoplasia with
elongated superior cerebellar peduncles, designated by the
authors as a “mild molar tooth sign.” Furthermore, poly-
microgyria was present in two siblings.19 Interestingly, all four
patients presented with ocular motor apraxia, whereas their
parents, who were heterozygotes of one of the identified
missense variants in SUFU, did not show any signs of Joubert
syndrome or COMA, suggesting that heterozygous truncating
variants have a more severe effect on SUFU function as a
repressor of the SHH pathway activity than heterozygous
hypomorphic missense variants which were identified in
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clinically unremarkable parents of patients with Joubert
syndrome by De Mori et al.19
Besides these two biallelic missense variants, De Mori
et al.19 additionally identified four individuals with hetero-
zygous, truncating variants in SUFU, c.598-1G>C, c.846dupC,
c.895C>T, and c.1192_1193delAA, which were either inher-
ited from a parent or occurred de novo (Fig. 3). No details on
the clinical presentation of these subjects were provided,
especially not regarding the severity of their phenotype and
the presence of a molar tooth sign, but in line with the
individuals presented in our study, De Mori et al.19 observed
no tumors or any signs of Gorlin syndrome in their subjects.
Parents inheriting these variants were indicated as healthy.
Still, based on the results of our study we observed a mild
neurodevelopmental phenotype during early childhood in
three parents including delayed motor and speech develop-
ment without signs of OMA (individual II.3, family 1),
impaired balance and poor motor coordination (individual
I.1, family 2), and ongoing ophthalmological treatment from
early childhood on (individual I.1, family 5). Clinical re-
evaluation of the subjects with heterozygous truncating
variants identified by De Mori et al.19 might help to determine
clinical significance of these variants and evaluate the clinical
spectrum of SUFU-associated variants.
Taken together, our findings indicate that heterozygous
truncating germline variants in SUFU alter SUFU-mediated
repression and increase basal activity of HH signaling
pathways, resulting in COMA and a neurodevelopmental
disorder with largely benign course, but some variability of
clinical phenotypes. Comparing the clinical and neuroimaging
features of the 15 subjects reported here with those known to
occur in Joubert syndrome, we suggest addressing the clinical
phenotype associated with heterozygous truncating germline
variants in SUFU as a forme fruste of Joubert syndrome.
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